Castle Biosciences, Inc., has announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of US$37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions.
Latham & Watkins LLP represents Castle Biosciences, Inc. in the public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Kiara Vaughn.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
